Overview of NPR’s Shortwave episode on the renaming of PCOS
This NPR Shortwave episode explains why PCOS (polycystic ovary syndrome) is being renamed PMOS (polyendocrine metabolic ovarian syndrome) and why the change matters far beyond semantics. Endocrinologist Dr. Helena Teede argues that the old name is misleading, stigmatizing, and has slowed research, diagnosis, and treatment for a condition that affects about 1 in 8 reproductive-aged women. The episode traces how patient advocacy, stronger scientific evidence, and global coordination finally made the reclassification possible.
Why “PCOS” was considered the wrong name
The old name doesn’t match the science
- The “cysts” in PCOS are not true cysts.
- What ultrasound shows are usually tiny, immature follicles, not abnormal cysts.
- More importantly, cysts are not required for diagnosis and are not the core problem.
It oversimplifies a hormonal disorder
- The disorder is driven by hormonal disruption, not just ovarian abnormalities.
- The old name framed it as mainly an ovary condition, when it actually affects:
- Metabolism
- Skin
- Hair
- Mental health
- Reproductive health
It can confuse and discourage patients
- Patients were often told they had a “polycystic ovary syndrome” even when the ovaries were not the main issue.
- That mismatch can make the diagnosis feel confusing, dismissive, or even invalidating.
What PMOS is intended to capture
The new name reflects a broader disease model
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome.
It is meant to highlight that the condition involves:
- Endocrine/hormonal disruption
- Metabolic problems
- Ovarian/reproductive effects
- A likely genetic basis
Why the new framing matters
- It recognizes that the disorder is system-wide, not just gynecological.
- It supports better understanding of symptoms that go beyond fertility.
What the condition looks like for patients
Common symptoms discussed
Dr. Teede describes several features that can appear in adolescence or early adulthood:
- Weight gain, often around the middle
- Increased body hair
- Thinning scalp hair
- Acne
- Skin pigmentation changes
- Irregular menstrual cycles
Mental health effects
- Higher rates of anxiety
- Increased mood disturbance and depression
- Emotional stress caused by visible symptoms, irregular periods, and uncertainty
Why diagnosis is often delayed
- Many patients are not immediately recognized as having the condition.
- Diagnosis can require seeing multiple providers.
- The episode notes that up to 70% remain undiagnosed according to the WHO.
Treatment: more than birth control
Birth control is often used as hormone treatment
- The oral contraceptive pill is commonly prescribed, but not just for contraception.
- It can help regulate hormonal symptoms and improve features like acne, irregular cycles, and androgen excess.
Other treatments mentioned
- Metformin for insulin resistance
- Anti-androgens for androgen excess
- Laser therapy and acne treatments for skin symptoms
Fertility is often misunderstood
- A major misconception is that patients with PCOS/PMOS cannot have children.
- Dr. Teede emphasizes that most women with the condition can have a family if they want one.
- Many only need tablet-based treatment to improve fertility, not IVF.
Consequences of delayed diagnosis
- Patients may assume they are infertile and delay family planning.
- That can add age-related fertility challenges on top of the condition itself.
Why the name change matters for research and care
Names shape funding and research
- Medical conditions often get studied only within the category their name creates.
- Because PCOS was framed as an ovary condition, research has been too narrow.
- That has contributed to:
- Few medications developed specifically for the disorder
- Limited evidence outside infertility
- Inadequate education and care pathways
The episode argues the naming problem has real-world effects
- Poor naming led to poor awareness.
- Poor awareness led to delayed diagnosis.
- Delayed diagnosis led to worse outcomes.
A broader critique of women’s health
- Dr. Teede suggests the condition was also neglected because it is a women’s health issue.
- The episode presents PCOS as an example of how women’s symptoms have historically been minimized or boxed in too narrowly.
How the reclassification happened
Why this time was different
Dr. Teede says the change succeeded because:
- The scientific evidence became too strong to ignore
- The process included patients, clinicians, researchers, and organizations globally
- There was major engagement, with 22,000 survey responses
- The name change was published in a prominent medical journal
Implementation plan
The transition is already underway through:
- WHO coding updates
- Revised international guidelines
- New textbooks
- Updated university curricula
- Professional training changes
- Multilingual patient resources
- Notices to journals and research funders to use “PMOS (formerly PCOS)”
Main takeaway
The episode makes the case that renaming PCOS to PMOS is not a cosmetic change—it is a necessary correction that could improve diagnosis, treatment, research, patient understanding, and long-term outcomes. The broader goal is not just a new label, but a new medical framework that finally matches the full reality of the disorder.
Notable insight
“When you put it in a box, it means that any research that is done tends to be funded from that box about that box.”
That line captures the central argument of the episode: a name can shape what medicine sees, studies, and treats.